Cost‐effectiveness analysis of pharmacogenetic‐guided antiseizure medication therapy based on the risk of HLA‐A*31:01 allele variants in Japan
HLA-A*31:01 screening before CBZ treatment is cost-effective in the Japanese population. These findings support incorporating genetic screening into Japan's healthcare coverage system to enable more personalized medicine approaches in epilepsy treatment.
Authors
- Takuji Nishida (ORCID: https://orcid.org/0000-0001-5391-4656)
- Yasushi Maruyama (ORCID: https://orcid.org/0009-0005-5734-0166)
- Kohei Ninomiya (ORCID: https://orcid.org/0000-0001-6232-0008)
- Shiori Ogawa (ORCID: https://orcid.org/0009-0002-5669-9263)
- Hiroki Kimura (ORCID: https://orcid.org/0000-0002-0610-7904)
- Masashi Ikeda (ORCID: https://orcid.org/0000-0001-6237-2449)
Institutions
- Fujita Health University (JP)
- National Epilepsy Center (JP)
- Nagoya University of Arts (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences Reports
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1002/pcn5.70249
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Forskningsrådet om Hälsa, Arbetsliv och Välfärd
- Japan Society for the Promotion of Science